86 related articles for article (PubMed ID: 3616906)
1. [Long-term hematologic changes caused by radioiodine treatment of thyroid cancer. II. Bone marrow changes including leukemia].
Günter HH; Schober O; Schwarzrock R; Hundeshagen H
Strahlenther Onkol; 1987 Jul; 163(7):475-85. PubMed ID: 3616906
[TBL] [Abstract][Full Text] [Related]
2. [Long-term hematologic changes caused by radioiodine treatment of thyroid cancer. I. Peripheral blood changes].
Schober O; Günter HH; Schwarzrock R; Hundeshagen H
Strahlenther Onkol; 1987 Jul; 163(7):464-74. PubMed ID: 3616905
[TBL] [Abstract][Full Text] [Related]
3. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer.
Glanzmann C
Strahlenther Onkol; 1992 Jun; 168(6):337-43. PubMed ID: 1621212
[TBL] [Abstract][Full Text] [Related]
4. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.
Pahlka RB; Sonnad JR
Health Phys; 2006 Sep; 91(3):227-37. PubMed ID: 16891898
[TBL] [Abstract][Full Text] [Related]
5. Acute leukemias after treatment with radioiodine for thyroid cancer.
Roldán Schilling V; Fernández Abellán P; Domínguez Escribano JR; Rivas González C; Mut Barberá E; Calatayud Cendra R
Haematologica; 1998 Aug; 83(8):767-8. PubMed ID: 9793274
[TBL] [Abstract][Full Text] [Related]
6. [Dosimetry of the hematopoietic system in radioiodine therapy of thyroid cancer].
Günter HH; Junker D; Schober O; Hundeshagen H
Strahlenther Onkol; 1987 Mar; 163(3):185-91. PubMed ID: 3563879
[TBL] [Abstract][Full Text] [Related]
7. [Bone marrow depression due to 131I treatment of thyroid cancer].
Keldsen N; Mortensen BT; Hansen HS
Ugeskr Laeger; 1988 Nov; 150(46):2817-9. PubMed ID: 3206692
[No Abstract] [Full Text] [Related]
8. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
[TBL] [Abstract][Full Text] [Related]
9. Preleukemia following large dose radioiodide therapy for metastatic thyroid carcinoma.
Yoosufani Z; Slavin JD; Hellman RM; Sethi SS; Spencer RP
J Nucl Med; 1987 Aug; 28(8):1348-50. PubMed ID: 3612295
[TBL] [Abstract][Full Text] [Related]
10. Ph+ acute lymphoblastic leukemia after iodine-131 treatment for thyroid cancer.
Piccirillo N; Sorà F; Laurenti L; Sica S; Chiusolo P; Leone G
Haematologica; 1999 Nov; 84(11):1050-1. PubMed ID: 10553170
[No Abstract] [Full Text] [Related]
11. Glycophorin A as a biological dosimeter for radiation dose to the bone marrow from iodine-131.
Jensen RH; Reynolds JC; Robbins J; Bigbee WL; Grant SG; Langlois RG; Pineda JD; Lee T; Barker WC
Radiat Res; 1997 Jun; 147(6):747-52. PubMed ID: 9189175
[TBL] [Abstract][Full Text] [Related]
12. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
13. [Changes in the blood picture after radioiodine therapy of thyroid cancer].
Grünwald F; Schomburg A; Menzel C; Steinecker S; Späth G; Bockisch A; Fimmers R; Hotze AL; Biersack HJ
Med Klin (Munich); 1994 Oct; 89(10):522-8. PubMed ID: 7808352
[TBL] [Abstract][Full Text] [Related]
14. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study.
Zettinig G; Hanselmayer G; Fueger BJ; Hofmann A; Pirich C; Nepp J; Dudczak R
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1428-32. PubMed ID: 12397459
[TBL] [Abstract][Full Text] [Related]
15. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
16. 131I dosimetry and thyroid stunning.
Gerard SK; Park HM
J Nucl Med; 2003 Dec; 44(12):2039-40; author reply 2040. PubMed ID: 14660731
[No Abstract] [Full Text] [Related]
17. Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: case report with literature review.
Grudeva-Popova J; Yaneva M; Zisov K; Ananoshtev N
J BUON; 2007; 12(1):129-32. PubMed ID: 17436415
[TBL] [Abstract][Full Text] [Related]
18. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
19. Radiation-induced leukemia at doses relevant to radiation therapy: modeling mechanisms and estimating risks.
Shuryak I; Sachs RK; Hlatky L; Little MP; Hahnfeldt P; Brenner DJ
J Natl Cancer Inst; 2006 Dec; 98(24):1794-806. PubMed ID: 17179481
[TBL] [Abstract][Full Text] [Related]
20. [Cytogenetic study of thyroid patients treated with external irradiation or radioiodine].
Katz N; Esik O; Füzy M; Gundy S
Orv Hetil; 1998 Jun; 139(25):1521-6. PubMed ID: 9676113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
